Andra AP fonden Raises Stake in Merck & Co., Inc. $MRK

Andra AP fonden increased its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 6.8% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 389,285 shares of the company’s stock after purchasing an additional 24,800 shares during the quarter. Andra AP fonden’s holdings in Merck & Co., Inc. were worth $50,023,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of the business. BlackRock Inc. lifted its holdings in shares of Merck & Co., Inc. by 0.5% during the 2nd quarter. BlackRock Inc. now owns 226,999,837 shares of the company’s stock valued at $29,169,479,000 after acquiring an additional 1,073,507 shares in the last quarter. State Street Corp increased its holdings in Merck & Co., Inc. by 0.9% in the 2nd quarter. State Street Corp now owns 120,413,256 shares of the company’s stock valued at $15,573,754,000 after purchasing an additional 1,087,583 shares in the last quarter. Wellington Management Group LLP raised its position in Merck & Co., Inc. by 2.3% in the second quarter. Wellington Management Group LLP now owns 86,249,283 shares of the company’s stock valued at $11,083,033,000 after purchasing an additional 1,934,312 shares during the period. Geode Capital Management LLC raised its position in Merck & Co., Inc. by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 60,047,984 shares of the company’s stock valued at $6,307,572,000 after purchasing an additional 249,110 shares during the period. Finally, Norges Bank acquired a new position in shares of Merck & Co., Inc. during the fourth quarter worth about $3,997,933,000. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently weighed in on MRK. HSBC upped their target price on Merck & Co., Inc. from $150.00 to $172.00 and gave the stock a “buy” rating in a research report on Thursday, September 10th. Scotiabank upped their price target on Merck & Co., Inc. from $136.00 to $155.00 and gave the stock a “sector outperform” rating in a report on Tuesday, June 30th. Morgan Stanley upgraded shares of Merck & Co., Inc. from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $116.00 to $179.00 in a research note on Thursday, August 20th. Wolfe Research boosted their target price on shares of Merck & Co., Inc. from $155.00 to $180.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 25th. Finally, Cantor Fitzgerald restated a “neutral” rating and issued a $120.00 target price on shares of Merck & Co., Inc. in a research note on Monday, July 6th. Seventeen equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $154.24.

Insider Buying and Selling

In other news, EVP David Maraldo sold 18,706 shares of the business’s stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $128.72, for a total value of $2,407,836.32. Following the completion of the sale, the executive vice president directly owned 18,212 shares in the company, valued at approximately $2,344,248.64. The trade was a 50.67% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Chirfi Guindo sold 15,000 shares of the company’s stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $131.00, for a total value of $1,965,000.00. Following the sale, the executive vice president directly owned 46,613 shares in the company, valued at approximately $6,106,303. This represents a 24.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 228,238 shares of company stock worth $29,977,783. 0.17% of the stock is currently owned by insiders.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The U.S. FDA approved an update to the WINREVAIR label to include data from the Phase 3 HYPERION trial in recently diagnosed adults with pulmonary arterial hypertension. The expanded evidence may support broader adoption of the product and strengthens Merck’s growth prospects beyond KEYTRUDA. FDA approves WINREVAIR label update
• Positive Sentiment: Japan approved KEYTRUDA QLEX, Merck’s first subcutaneous KEYTRUDA formulation, for all locally approved KEYTRUDA indications. The faster, more convenient alternative to intravenous administration could improve patient and clinician convenience while helping defend KEYTRUDA’s international franchise. KEYTRUDA QLEX approved in Japan
• Positive Sentiment: The European Medicines Agency’s CHMP backed the KEYTRUDA-plus-PADCEV combination as a perioperative treatment for eligible patients with resectable muscle-invasive bladder cancer. If formally approved, the decision would expand the combination’s addressable market and reinforce Merck’s oncology pipeline. CHMP backs Keytruda-Padcev combination
• Neutral Sentiment: The average sell-side recommendation remains equivalent to a Buy, but analyst optimism is not necessarily a reliable indicator of future performance. Investors should weigh the ratings against Merck’s earnings outlook, competitive risks and valuation. Analyst view on Merck
• Negative Sentiment: A separate analysis called Merck overvalued and overbought, highlighting potential profit-taking after the stock’s strong run. With shares near their 52-week high and a reported trailing P/E above 120, valuation remains a risk even as new product approvals improve the growth narrative. Merck valuation downgrade

Merck & Co., Inc. Stock Up 1.2%

MRK traded up $1.78 during trading on Tuesday, hitting $151.28. The company had a trading volume of 3,174,174 shares, compared to its average volume of 10,748,557. The company has a market cap of $373.23 billion, a PE ratio of 121.12, a P/E/G ratio of 6.39 and a beta of 0.21. The business has a 50-day moving average of $138.97 and a 200-day moving average of $125.44. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.32 and a quick ratio of 1.10. Merck & Co., Inc. has a 1-year low of $77.58 and a 1-year high of $156.92.

Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The company had revenue of $16.61 billion during the quarter, compared to the consensus estimate of $16.37 billion. During the same quarter in the previous year, the firm earned $2.13 EPS. The company’s revenue was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, analysts forecast that Merck & Co., Inc. will post 2.76 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be issued a dividend of $0.85 per share. This represents a $3.40 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date of this dividend is Tuesday, September 15th. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 272.00%.

About Merck & Co., Inc.

Merck & Co, Inc is a global healthcare company that develops, manufactures, and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets worldwide through its Human Health and Animal Health businesses.

Merck’s pharmaceutical portfolio includes oncology, infectious disease, cardiology, immunology, and other therapeutic areas. Its products include Keytruda, an immunotherapy used to treat various cancers; Gardasil, a vaccine that helps protect against human papillomavirus (HPV); and Januvia, a treatment for type 2 diabetes.